ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 646,79
1,01%
Dow Jones
38 834,86
0,00%
DAX
18 162,47
0,53%
Brent Oil
84,705
0,01%
Bitcoin
66 168,69
1,85%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Poseida Therapeutics Inc (PSTX)

  7. Poseida Therapeutics Inc (PSTX) Actualités

PSTX

Poseida Therapeutics (PSTX)

Poseida Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PSTX
DateHeureSourceTitreSymboleSociété
18/06/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
18/06/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
03/06/202422h05PR Newswire (US)Poseida Therapeutics Announces Virtual 2024 Annual Meeting of StockholdersNASDAQ:PSTXPoseida Therapeutics Inc
14/05/202422h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSTXPoseida Therapeutics Inc
14/05/202422h05PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024NASDAQ:PSTXPoseida Therapeutics Inc
09/05/202415h00PR Newswire (US)Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
06/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PSTXPoseida Therapeutics Inc
02/05/202403h30PR Newswire (US)Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyNASDAQ:PSTXPoseida Therapeutics Inc
01/05/202421h25AllPennyStocks.comBiotech Soars on Research Collaboration And License Agreement ReleaseNASDAQ:PSTXPoseida Therapeutics Inc
18/04/202414h00PR Newswire (US)Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
17/04/202415h00PR Newswire (US)Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusNASDAQ:PSTXPoseida Therapeutics Inc
08/04/202418h00PR Newswire (US)Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
01/04/202422h05PR Newswire (US)Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PSTXPoseida Therapeutics Inc
25/03/202421h05PR Newswire (US)Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical OfficerNASDAQ:PSTXPoseida Therapeutics Inc
19/03/202421h05PR Newswire (US)Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceNASDAQ:PSTXPoseida Therapeutics Inc
13/03/202421h05PR Newswire (US)Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
07/03/202422h07PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:PSTXPoseida Therapeutics Inc
08/02/202422h10Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PSTXPoseida Therapeutics Inc
04/01/202414h00PR Newswire (US)Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key MilestonesNASDAQ:PSTXPoseida Therapeutics Inc
11/12/202316h31Dow Jones NewsPoseida Therapeutics Shares Climb on Positive Data for Blood Cancer TreatmentNASDAQ:PSTXPoseida Therapeutics Inc
10/12/202318h00PR Newswire (US)Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
09/11/202322h05PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023NASDAQ:PSTXPoseida Therapeutics Inc
07/11/202314h00PR Newswire (US)Poseida Therapeutics to Present at Two Upcoming Investor ConferencesNASDAQ:PSTXPoseida Therapeutics Inc
02/11/202314h01PR Newswire (US)Poseida Therapeutics to Present at the 65th ASH Annual Meeting and ExpositionNASDAQ:PSTXPoseida Therapeutics Inc
09/10/202322h30PR Newswire (US)Poseida Therapeutics Announces Leadership TransitionNASDAQ:PSTXPoseida Therapeutics Inc
14/08/202322h41Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:PSTXPoseida Therapeutics Inc
11/08/202322h48Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:PSTXPoseida Therapeutics Inc
08/08/202322h05PR Newswire (US)Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023NASDAQ:PSTXPoseida Therapeutics Inc
07/08/202316h41Dow Jones NewsPoseida Therapeutics Shares Leap on Astellas InvestmentsNASDAQ:PSTXPoseida Therapeutics Inc
07/08/202315h58Dow Jones NewsPoseida Therapeutics in $50 Million Investment Deal With AstellasNASDAQ:PSTXPoseida Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PSTX

Dernières Valeurs Consultées

COIN
ELTUSD
ETH Light
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés